Keywords: promising, data, first, fusion, inhibitor, t-20, trimeris

Promising data with first fusion inhibitor T-20

Article | 20 July 2000

Print This

Trimeris and Hoffmann-La Roche have revealed promising data from a48-week trial of T-20, the first in a new class ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in